Publications by authors named "H R Henney"
Article Synopsis
- Levodopa (LD) is crucial for managing motor symptoms in Parkinson's disease but has unpredictable OFF periods due to variability in absorption.
- CVT-301, a levodopa inhalation powder, aims to treat these OFF periods and was tested alongside oral carbidopa/levodopa (CD/LD) in patients.
- In the study, 23 patients showed that CVT-301 had a faster onset of action compared to oral CD/LD, indicating its potential effectiveness for quick relief of OFF episodes.
Background: Dalfampridine extended release (ER) improves walking in people with multiple sclerosis (MS), as demonstrated by walking speed improvement. This exploratory study evaluated treatment effects of dalfampridine-ER on gait, balance, and walking through treatment withdrawal and reinitiation.
Methods: Dalfampridine-ER responders, based on Timed 25-Foot Walk (T25FW) assessment before study entry, were included in this open-label, three-period, single-center study.
Article Synopsis
- The study aimed to evaluate the safety and tolerability of dalfampridine extended release (D-ER) in individuals with chronic post-ischemic stroke deficits, while also assessing its potential effects on sensorimotor function.
- Using a double-blind, placebo-controlled crossover design, 83 participants were assessed for various endpoints, including safety, walking speed, and other motor assessments; results showed D-ER was generally well tolerated with no new safety concerns.
- Analyses indicated that participants treated with D-ER experienced a statistically significant improvement in walking speed compared to placebo, suggesting potential benefits of D-ER in enhancing lower extremity function after stroke.
Background: Dalfampridine extended-release (ER) tablets, 10 mg twice daily, have been shown to improve walking in people with multiple sclerosis. We evaluated the safety and efficacy of dalfampridine-ER 5 mg compared with 10 mg.
Methods: Patients were randomized to double-blind treatment with twice-daily dalfampridine-ER tablets, 5 mg (n = 144) or 10 mg (n = 143), or placebo (n = 143) for 4 weeks.
Background: In Phase 3 double-blind trials (MS-F203 and MS-F204), dalfampridine extended release tablets 10 mg twice daily (dalfampridine-ER; prolonged-release fampridine in Europe; fampridine modified or sustained release elsewhere) improved walking speed relative to placebo in patients with multiple sclerosis (MS).
Objectives: Evaluation of long-term safety and efficacy of dalfampridine-ER in open-label extensions (MS-F203EXT, MS-F204EXT).
Methods: Patients received dalfampridine-ER 10 mg twice daily; and had Timed 25-Foot Walk (T25FW) assessments at 2, 14 and 26 weeks, and then every 6 months.